Credevo, Singapore (2026)

02/03/2026

The next generic drug opportunity wave is already here, and the window to act is narrowing fast. ⏳

The pharmaceutical industry is approaching a patent cliff between 2026 and 2030, with approximately $180 to $200 billion in annual pharmaceutical revenue at risk from blockbuster drugs losing exclusivity. 🚨

For generic developers, this is one of the most significant opportunity windows of the decade. But here is where most programs stumble: delayed or poorly structured Bioequivalence (BE) planning.

Late BE study initiation means missed first-to-file advantages, compressed regulatory timelines, and costly development rework that erodes your competitive position before a single tablet reaches the market.

This is exactly the problem Credevo's BE Protocol Catalogue is built to solve. 🔬

Our ready-to-use BE study protocols for high-value reference listed drugs approaching loss of exclusivity between 2026 and 2030 are:
✅ Aligned with current FDA and EMA regulatory expectations
✅ Built on standard BE scientific frameworks covering PK endpoints, sampling strategy, and analytical considerations
✅ Complete with study design, rationale, statistical methodology, and safety framework
✅ Ready for immediate operational planning

The sponsors who plan BE studies earlier will reduce development risk and stay ahead in an increasingly competitive generic landscape. 📈

Got an upcoming generic program or looking to map out your BE strategy? Let's figure it out together.
👉 Browse our bioequivalence study protocol catalogue and identify upcoming generic opportunities:
https://credevo.com/s/bioequivalence-study-protocol-catalogue/

👉 Looking to discuss a specific product or strategy?
📩 Drop us a message here: https://credevo.com/contact

27/02/2026

🚨 Your generic drug is scientifically sound. But is it regulatory-ready for every market you want to enter?

A BA/BE study that clears FDA review can still face rejection when submitted to EMA, PMDA, ANVISA, or CDSCO. The science may be identical. The regulatory expectations are not.
And the stakes are real. The global generics market is projected to nearly double to USD $950 billion by 2034. Yet study failures remain common, often because only 45% of sponsors perform joint power calculations for both Cmax and AUC endpoints, leaving studies underpowered before a single subject is dosed.

📊 Every major agency applies its own layer of requirements:
FDA tightens NTI drug criteria with replicated crossover designs. EMA narrows the AUC acceptance window to 90.00 to 111.11% for NTI drugs. PMDA, Health Canada, and emerging market regulators add population-specific and documentation-specific demands on top.

A weak protocol signals a weak study, even before data is generated.
💡 That is exactly the problem we solve at Credevo.

Our ready-to-use BA/BE study protocols are built for multi-regional submissions across FDA, EMA, PMDA, CDSCO, ANVISA, and more, helping you reduce deficiency letters, avoid costly redesigns, and accelerate time-to-approval.
📄 Browse our protocol catalogue: https://credevo.com/s/bioequivalence-study-protocol-catalogue/

👉 Connect with our team: https://credevo.com/contact

26/02/2026

Clinical trial budget pressure often begins during protocol planning. 💡

As protocols become more complex, ex*****on becomes heavier for sites and costs rise quickly. Small inefficiencies at the design stage can translate into significant financial impact once a study is underway.

High screen failure rates, slow enrollment, operational delays, and protocol amendments are often linked to early design decisions. 📉
Eligibility criteria may limit real-world recruitment. Visit schedules may not reflect site capacity.

Once a protocol is finalized, changes become expensive across all participating sites. 💰
Involving investigators during protocol preparation helps validate recruitment assumptions and operational realities before budgets and timelines are locked. 🤝

At Credevo, we support sponsors with feasibility, investigator input, and protocol optimization at this stage to improve cost predictability and study readiness.

📩 Planning a new study? Let’s strengthen your protocol before costs escalate.
👉 https://credevo.com/contact

25/02/2026

🚨 Over 85% of clinical trials face delays, and a single day lost in drug development can cost sponsors more than $600,000.

For global sponsors running trials in Japan, customs and logistics bottlenecks are among the biggest, and most underestimated, contributors.

🇯🇵 Japan's PMDA operates within one of the world's most rigorous regulatory frameworks. A single documentation error or customs misclassification can hold shipments for up to 14 days, and 68% of life science organizations have experienced exactly this. For temperature-sensitive IMPs, these delays do not just cost money; they risk data integrity and patient safety.

The two most common reasons shipments are stopped? Incomplete documentation and the absence of a recognized, in-country Importer of Record (IOR).

This is why IOR and EOR services are not a logistics add-on. They are a regulatory necessity.
✅ The right IOR and EOR partner in Japan delivers:
🔹 Full PMDA and PMD Act compliance
🔹 Accurate documentation, translation and customs liaison
🔹 Cold chain management with real-time visibility
🔹 Up to 20% reduction in overall supply costs
🔹 Trial timelines accelerated by 1 to 2 weeks on average

At Credevo, our PMDA-aligned IOR and EOR services ensure your IMPs and trial materials move compliantly and on time, every time. Japan is complex. Your supply chain does not have to be.

📩 Let us take it from here 👉 https://credevo.com/contact

24/02/2026

Most generic drug programs don't fail because of a bad molecule. They fail because of where and how BA/BE studies are run.

Delayed ethics approvals. Bioanalytical gaps. Sites that don't survive FDA inspection. In 2025, the regulatory bar has risen across every major market, and a single deficiency response can cost you 12 to 18 months of lead time.

The global generic drugs market is projected to reach USD 817 billion by 2034 (Towards Healthcare, 2025). The window to capture that opportunity is narrow. Your BA/BE program cannot be the bottleneck.

India has become the global answer to this challenge. It supplies 20% of global generic drug exports by volume (IBEF), hosts the highest number of US FDA-approved plants outside the US, and delivers BA/BE data formally accepted by the FDA, EMA, Health Canada, TGA, ANVISA, and all ASEAN regulators.

One well-designed study from an Indian site can support simultaneous filings across multiple stringent markets. That is strategy, not just cost savings.

Got a BA/BE program in the works? Our team would love to help you think it through. 👉 https://credevo.com/contact

23/02/2026

Nearly 1 in 2 clinical trial protocol amendments are avoidable.

Yet each one still costs 2–3 months and significant budget and the root cause is often traceable to decisions made at the drafting stage.

Over the past decade, protocol complexity has grown substantially. More endpoints, more procedures, more eligibility nuance. When medical, statistical, regulatory, and operational perspectives aren't aligned from the start, the downstream consequences are predictable: IRB queries, site confusion, recruitment delays, regulatory pushback.

What's less discussed is how much of this is preventable with stronger protocol design upfront.

A well-constructed protocol isn't just a compliance document. It's the operational and scientific backbone of your study and the difference between a smooth IND submission and a cycle of amendments that erodes your timeline and budget before the first patient is enrolled.

At Credevo, we work with sponsors and research teams to develop protocols that are scientifically rigorous, ICH GCP aligned, and built for real-world site ex*****on, not just regulatory submission.

If your next study is in the planning phase, that's the right moment to get this right.
👉 https://credevo.com/contact

Sources: Getz et al., Therapeutic Innovation & Regulatory Science | Getz et al., Nature Reviews Drug Discovery | Tufts CSDD

19/02/2026

🔎 Did You Know Most HR⁺/HER2⁻ Breast Cancer Trials Face Preventable Recruitment Delays?

HR⁺/HER2⁻ accounts for nearly 70% of all breast cancer cases (American Cancer Society: https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html).

Yet trials in this population often struggle with:
• Recruitment delays of 6 to 12 months
• Eligibility criteria excluding up to 70% of real-world patients (JAMA Oncology: https://jamanetwork.com/journals/jamaoncology/fullarticle/2730501)
• Regional differences in standard of care impacting comparator arms
• Biomarker testing bottlenecks and operational complexity
The consequence is slower data generation, rising costs, and delayed patient access to innovation.

💡 The solution: Early site and investigator engagement

Engaging investigators during protocol development strengthens both feasibility and scientific rigour.
Early collaboration helps sponsors to:
✅ Align eligibility criteria with real-world clinical practice
✅ Select regionally appropriate comparators
✅ Plan biomarker testing logistics early
✅ Reduce site burden through patient-friendly design
✅ Improve diversity and representation strategies

Evidence from Nature Reviews Clinical Oncology shows that protocol complexity and misalignment with routine practice are key drivers of recruitment failure (https://www.nature.com/articles/s41571-019-0237-2). Addressing these factors early improves enrolment performance and data quality.

When feasibility insights are integrated upfront, trials become more patient-centred, operationally practical, scientifically robust, and faster to recruit.
At Credevo, we provide global oncology feasibility intelligence and protocol optimisation support tailored for HR⁺/HER2⁻ programs.

📩 Partner with Credevo for early site engagement and oncology feasibility expertise to optimise your HR⁺/HER2⁻ breast cancer trials and accelerate recruitment timelines.
Connect with us: https://credevo.com/contact

18/02/2026

Lenvatinib Mesylate – Preparing for a Strategic Oncology LOE Window

Lenvatinib mesylate, marketed as Lenvima by Eisai, is an oral multi-targeted tyrosine kinase inhibitor (TKI) approved for differentiated thyroid cancer, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma.
Its expanding role in combination regimens particularly with Keytruda has reinforced its position as a high-value oncology asset across major markets.

Development Considerations
Oral small-molecule TKI with defined ANDA/abridged regulatory pathways
Bioequivalence strategy must address fasting/fed design and oncology safety monitoring
Robust impurity profiling and stability programs critical for global filings
Coordinated CMC, clinical, and regulatory planning key to competitive timelines
Loss of Exclusivity Snapshot
United States: Core patent protections expected to expire between 2026–2028, subject to patent term extensions and litigation outcomes
European Union: Market-specific expiries anticipated around 2026–2027
Japan & Rest of World: Similar protection windows generally falling within 2026–2028
With a concentrated LOE window approaching, lenvatinib represents a significant opportunity for oncology-focused generic sponsors. Early patent assessment, BE protocol optimization, and supply chain readiness will be decisive for first-wave participation.

Planning your development strategy? Access our bioequivalence study protocol:
👉 https://credevo.com/s/lenvatinib-bioequivalence-study-protocol/

17/02/2026

Tapentadol Hydrochloride – A Timely CNS Generic Development Opportunity

Tapentadol hydrochloride is a centrally acting analgesic with a dual mechanism of action: µ-opioid receptor agonism and norepinephrine reuptake inhibition. Marketed by Grünenthal under the brand Nucynta (and through regional partners), it is approved for the management of moderate to severe acute pain, chronic pain, and neuropathic pain associated with diabetic peripheral neuropathy.

Its differentiated pharmacology and established positioning in pain management make it a strategically attractive molecule in the CNS generic space.

Sustained Demand Factors

Sustained demand is supported by:
Broad utilisation in acute and chronic pain settings
Dual mechanism offering an alternative to traditional opioids
Immediate-release (IR) and extended-release (ER) formulations
Consistent prescribing across orthopaedic, postoperative, and neuropathic indications
Chronic therapy segments driving steady volume
Development Considerations
From a development standpoint, tapentadol hydrochloride represents a structured small-molecule generic opportunity. Established pharmacokinetic data, well-defined bioequivalence (BE) pathways for IR and ER products, and clear regulatory guidance enable efficient program planning. However, formulation strategy particularly for extended-release versions requires robust control of release kinetics and alcohol dose-dumping assessments to meet regulatory expectations.

Loss of Exclusivity Snapshot (as of 2026)

In the United States, primary patent protections for Nucynta ER formulations expire on December 27, 2025, while Nucynta IR exclusivity extends to January 3, 2027, with settlements pushing some generic ER entry to July 1, 2027
Additional formulation and method patents, such as US7994364 (expiring 2025) and US8536130 (expiring 2028), have influenced staggered launch timelines
In the European Union and other markets, exclusivity landscapes vary by country and specific presentation
Controlled substance scheduling necessitates compliance with DEA and equivalent authority requirements in key markets

Strategic Next Steps
As pain management markets continue to evolve, early alignment on CMC development, BE study design, and regulatory pathway is essential to capture first-wave or early-entry positioning.

Planning a tapentadol hydrochloride generic program? Access our ready-to-use bioequivalence study protocol:
👉 https://credevo.com/s/tapentadol-hydrochloride-bioequivalence-study-protocol/

16/02/2026

Fostamatinib Disodium – A Targeted Hematology Generic Opportunity

Fostamatinib disodium, marketed as Tavalisse by Rigel Pharmaceuticals, is an oral spleen tyrosine kinase (SYK) inhibitor approved for chronic immune thrombocytopenia (ITP) in adults with insufficient response to prior therapy. Its targeted mechanism and role in refractory ITP position it as a differentiated asset in the specialty hematology segment.

Sustained demand is supported by:
• Established role in second-line and later chronic ITP
• Oral alternative to splenectomy, rituximab, and TPO receptor agonists
• Chronic administration driving predictable utilization
• Reimbursement coverage across major markets

From a development perspective, fostamatinib disodium represents a clearly defined small-molecule generic pathway. Published PK data, standard crossover bioequivalence (BE) study designs, and regulatory precedent support efficient development planning. Early entrants in specialty hematology generics can capture meaningful share, particularly where limited branded competition exists.

Loss of Exclusivity Snapshot
• In the United States, key composition-of-matter patents are expected to expire in 2027, opening structured generic entry pathways
• In the European Union, primary patent protections are projected to lapse around 2027–2028, subject to SPC status in select member states
• Regulatory data exclusivity in the EU (8+2+1 framework) runs through approximately 2029, depending on country-specific timelines
• Secondary patents relating to formulation and specific claims may extend into the early 2030s, potentially influencing launch sequencing
As barriers lift over the next several years, readiness in CMC development, BE ex*****on, and regulatory strategy will determine early advantage.

Planning a fostamatinib disodium generic program?
Access our ready-to-use bioequivalence study protocol:
👉 https://credevo.com/s/fostamatinib-disodium-bioequivalence-study-protocol/

13/02/2026

Tofacitinib Citrate – A High-Value Immunology Generic Opportunity

Tofacitinib citrate, marketed as Xeljanz by Pfizer, is a widely used oral JAK inhibitor for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Its role in chronic autoimmune management makes it a durable revenue driver in the global immunology market.

Sustained demand is driven by:
• Strong guideline positioning in moderate-to-severe RA
• Multi-indication use across inflammatory diseases
• Oral alternative to injectable biologics
• Long-term maintenance therapy with established reimbursement

From a development perspective, tofacitinib offers a clearly defined small-molecule generic pathway. Standard crossover bioequivalence (BE) designs, established PK data, and regulatory precedent support structured and efficient development programs. Early entrants in high-value immunology segments often capture meaningful initial market share.

Loss of Exclusivity Snapshot
• In the United States, composition-of-matter and key exclusivity protections for Xeljanz have reached or are approaching expiry, enabling structured generic entry pathways
• In the European Union, data and market exclusivity milestones have lapsed, opening opportunities across member states
• Secondary patents related to formulation and specific indications may influence launch sequencing in certain markets
• Health systems globally are actively pursuing cost-containment strategies, positioning JAK inhibitors as prime candidates for generic substitution

As barriers lift, readiness in CMC, BE strategy, and regulatory ex*****on will determine early advantage.

Planning a tofacitinib citrate generic program?
Access our ready-to-use bioequivalence study protocol:
👉 https://credevo.com/s/tofacitinib-citrate-bioequivalence-study-protocol/

12/02/2026

Brivaracetam - A Strategic Opportunity in CNS Generics

Brivaracetam has become an important therapy for focal (partial-onset) seizures in patients with epilepsy, forming a resilient revenue-generating asset within the global central nervous system (CNS) marketplace. With epilepsy affecting tens of millions of individuals worldwide and chronic antiepileptic treatment being a mainstay of care, demand for well-established, guideline-aligned therapies continues to be durable and substantial.

Ongoing adoption is supported by:
• Strong clinical guidelines recommending adjunctive therapy for focal seizures
• Favorable tolerability and rapid onset relative to older antiepileptic drugs
• Use across adult and pediatric populations in long-term management
• Chronic therapy with high persistence and switching costs

From a development vantage point, brivaracetam presents a well-defined bioequivalence pathway. As a small-molecule AED with established clinical use and regulatory precedence, it allows for clearly structured BE study designs when backed by rigorous analytical methods and thoughtful protocol planning.

Historically, early generic entrants in high-value CNS categories often capture a disproportionate share of initial market conversion. First approvals can secure significant early generic volume, particularly in markets with strong substitution policies and rapid payer uptake.

Loss of Exclusivity Context
• In the United States, key patents on brivaracetam’s active ingredient and use are scheduled to expire in 2026, enabling generic entry pathways thereafter
• In the European Union, regulatory exclusivity linked to Briviact also reaches key milestones in 2026 across member states
• Secondary formulation/process patents may impact launch timing in select regions and require strategic consideration
• Major payers and health systems are already positioning for rapid generic substitution post-LOE

As loss of exclusivity approaches, readiness across CMC development, bioequivalence design, and regulatory strategy will determine who captures early market share.

Planning a brivaracetam generic program?
Access our ready-to-use bioequivalence study protocol to accelerate development timelines and regulatory preparedness:
https://credevo.com/s/brivaracetam-bioequivalence-study-protocol/

Credevo

02/03/2026

27/02/2026

26/02/2026

25/02/2026

24/02/2026

23/02/2026

19/02/2026

18/02/2026

17/02/2026

16/02/2026

13/02/2026

12/02/2026

Address

Website

Alerts

Shortcuts

Featured

Share

Category